



HEART VALVE DISEASE

Working together to create a better patient journey

Heart valve disease is a common, serious, but treatable cardiovascular condition. If left untreated, the most common form of heart valve disease (aortic stenosis), when severe, is associated with a mortality rate of 25% to 50% per year.¹



Symptoms, if they occur, often mimic general signs of aging, and people experiencing them may not think to consult a doctor.

With Canada's population growing older, the burden of heart valve disease is on the rise.²

68%

Hospitalizations for heart valve disease increased by 68% between 2007 and 2017.³



Effective treatments exist and can markedly prolong life and improve quality of life.⁴⁻⁸

For 94% of people, replacement valves continue to function well 10 years after surgery.⁹

Cumulative delays in the care journey mean people are often treated too late:



- 1 late detection
- late access to echocardiogram (for diagnosis)
- 3 late intervention



Not providing people with timely treatment results in avoidable deaths, significant compromises to individuals' quality of life and a huge cost to the health system owing to frequent stays in hospital, use of intensive care units and long-term rehabilitation.¹⁰⁻¹²



What needs to change?

All people with heart valve disease should have rapid access to high-quality care, offered by a dedicated multidisciplinary team. Individuals should actively participate in shared decision-making related to their care and patient education should be embedded across the care journey.

TO ENABLE THIS TO HAPPEN, WE NEED:



2

3

4

DETECTION IN PRIMARY CARE

- + **Practitioners alerted to red-flag signs and symptoms** of heart valve disease, disease progression and available treatment options
- Annual checks with stethoscope as part of routine check-ups for those over 60 or with pre-existing valve conditions
 - + **Integration of digital tools** to aid detection in primary care



REFERRAL, WORK-UP AND MONITORING

- + **Prompt referral to heart valve clinics**for routine review and monitoring
 - + Clear point of contact for patients to report any changes in their condition and receive follow-up care



AWARENESS

- + **National and regional awareness** campaigns to raise public awareness of heart valve symptoms
- + **Public funding for patient organizations** to provide ongoing support and information to patients



DIAGNOSIS VIA ECHOCARDIOGRAM

- + Referrals to echocardiography within 2 weeks for symptomatic patients and 6 weeks for asymptomatic patients
- + Workforce planning to increase the number of trained professionals performing echocardiograms
- + Consistent quality ensured through training, quality assurance programs and standardized templates for reporting results to primary care





TREATMENT AND LONG-TERM FOLLOW-UP

- + Individualized treatment choices selected through shared decision-making with the patient
- + Timely uptake of innovative and evidence-based technologies using existing health technology pathways
- + Cardiac rehabilitation including physical and psychological support
- + Routine follow-up post-treatment that includes annual echocardiogram



Heart valve disease: working together to create a better patient journey is a report commissioned by Heart Valve Voice Canada and written by The Health Policy Partnership. It has been adapted from a European report by the same title, which was commissioned by the Global Heart Hub and written by The Health Policy Partnership in 2020. To find out more about heart valve disease in Canada, visit heartvalvevoice.ca

REFERENCES

- 1. Lange R, et al. 2016. JACC Cardiovasc Interv 9(24): 2541-54
- 2. d'Arcy J, et al. 2011. Heart 10.1136/hrt.2010.205096
- 3. Botly LCP, *et al.* 2020. *Can J Cardiol* 36(7): 1081-90
- 4. Chambers JB, et al. 2013. Heart 99(23): 1714-16
- 5. Nkomo VT, *et al.* 2006. *Lancet* 368(9540): 1005-11
- 6. Mo Y, et al. 2018. Eur J Cardiothorac Surg 53(3): 569-75
- 7. Vahanian A, et al. 2012. Eur Heart J 33(19): 2451-96
- 8. Trochu J-N, et al. 2015. Arch Cardiovasc Dis 108(2): 88-96
- 9. Foroutan F, et al. 2016. BMJ 354: i5065 10. Clark MA, et al. 2012. Circ Cardiovasc Qual Outcomes 5(5): 697-704
- 11. Coffey S, *et al.* 2016. *Heart* 102(1): 75-85
- 12. Danielsen R, et al. 2014. Int J Cardiol 176(3): 916-22